Agilent Applied sciences has agreed to amass pathology options supplier Biocare Medical in a money transaction value $950m.
The acquisition will give life sciences agency Agilent management of California-based Biocare’s immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH) options which are designed to help improved affected person well being outcomes throughout oncology and broader scientific pathology.
With entry to those merchandise, Agilent highlighted that it expects the mix of its international operations with Biocare’s US industrial presence to create a stronger platform to raised serve a “broader base” of analysis and scientific prospects.
On condition that Biocare holds greater than 300 specialised antibodies, Agilent added that it additionally anticipates the acquisition to broaden its capability to develop and commercialise new in vitro diagnostic (IVD) antibodies.
Agilent expects the transaction to shut by the fourth quarter of its 2026 fiscal 12 months and turn out to be accretive to its earnings per share (EPS) roughly 12 months following shut. As soon as the transaction completes, Biocare will turn out to be a part of Agilent’s Life Sciences and Diagnostics Markets Group (LDG) enterprise section.
In Q1 of fiscal 12 months 2026, Agilent’s LDG enterprise generated income of $679m, indicative of 5% development year-over-year (YoY).
Agilent CEO Padraig McDonnell stated the acquisition of Biocare would improve the corporate’s pathology portfolio, with the transfer resonating with the corporate’s technique to “drive long-term development by customer-centric innovation and disciplined capital allocation”.
“Collectively, this complementary mixture will allow us to raised serve our valued pathology prospects throughout scientific and analysis settings, speed up innovation and help long-term worth creation for our shareholders,” McDonnell continued.
Biocare has been below the stewardship of VC corporations Excellere Companions and GHO Capital since 2021, having skilled consecutive double-digit development because the VC corporations grew to become the corporate’s key buyers. In 2025, the corporate generated income of $90m.
Biocare CEO Luiz de Luzuriaga commented: “After years of great progress, that is the precise time to maneuver ahead with new possession aligned with our dedication to product high quality, scientific affect and worth creation.”
Ought to Agilent’s settlement to amass Biocare go forward, it’ll signify the corporate’s second big-money acquisition in as a few years. In September 2024, Agilent accomplished the $925m acquisition of Canadian contract improvement and manufacturing organisation (CDMO) BIOVECTRA.
